Drugs / MK-5172A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02115321 | May 2014 → Mar 2015 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-5172A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02115321 ↗ |
| Route | Oral | “MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.” NCT02115321 ↗ |